Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using semaglutide therapy than when they are not using the drug, according to findings from a retrospective study.
Prior studies have produced conflicting findings regarding the risk for nonarteritic anterior ischemic optic neuropathy (NAION), a form of optic neuropathy that could potentially cause blindness, while using semaglutide (Ozempic/Wegovy, Novo Nordisk). As Healio previously reported, data from Massachusetts Eye and Ear that was published in JAMA Ophthalmology in